Literature DB >> 9149259

Current concepts in neuro-oncology: the cell cycle--a review.

P B Dirks1, J T Rutka.   

Abstract

Uncontrolled cellular proliferation is the hallmark of human malignant brain tumors. Their growth proceeds inexorably, in part because their cellular constituents have an altered genetic code that enables them to evade the checks and balances of the normal cell cycle. Recently, a number of major advances in molecular biology have led to the identification of several critical genetic and enzymatic pathways that are disturbed in cancer cells resulting in uncontrolled cell cycling. We now know that the progression of a cell through the cell cycle is controlled in part by a series of protein kinases, the activity of which is regulated by a group of proteins called cyclins. Cyclins act in concert with the cyclin-dependent kinases (CDKs) to phosphorylate key substrates that facilitate the passage of the cell through each phase of the cell cycle. A critical target of cyclin-CDK enzymes is the retinoblastoma tumor suppressor protein, and phosphorylation of this protein inhibits its ability to restrain activity of a family of transcription factors (E2F family), which induce expression of genes important for cell proliferation. In addition to the cyclins and CDKS, there is an emerging family of CDK inhibitors, which modulate the activity of cyclins and CDKs. CDK inhibitors inhibit cyclin-CDK complexes and transduce internal or external growth-suppressive signals, which act on the cell cycle machinery. Accordingly, all CDK inhibitors are candidate tumor suppressor genes. It is becoming clear that a common feature of cancer cells is the abrogation of cell cycle checkpoints, either by aberrant expression of positive regulators (for example, cyclins and CDKs) or the loss of negative regulators, including p21Cip1 through loss of function of its transcriptional activator p53, or deletion or mutation of p16ink4A (multiple tumor suppressor 1/CDKN2) and the retinoblastoma tumor suppressor protein. In this review, we describe in detail our current knowledge of the normal cell cycle and how it is disturbed in cancer cells. Because there have now been a number of recent studies showing alterations in cell cycle gene expression in human brain tumors, we will review the derangements in both the positive and negative cell cycle regulators that have been reported for these neoplasms. A thorough understanding of the molecular events of the cell cycle may lead to new opportunities by which astrocytoma cell proliferation can be controlled either pharmacologically or by gene transfer techniques.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9149259     DOI: 10.1097/00006123-199705000-00025

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  23 in total

1.  Differential proliferation dependence of alpha and beta damage in X-irradiated Chinese hamster cells.

Authors:  D Bartkowiak; W Nothdurft; E M Röttinger
Journal:  Strahlenther Onkol       Date:  1999-05       Impact factor: 3.621

2.  Unusual MR spectroscopic imaging pattern of an astrocytoma: lack of elevated choline and high myo-inositol and glycine levels.

Authors:  Ana Londoño; Mauricio Castillo; Diane Armao; Lester Kwock; Kinuko Suzuki
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

3.  Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique.

Authors:  H E Miettinen; N Paunu; I Rantala; H Kalimo; L Paljärvi; H Helin; H Haapasalo
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

Review 4.  Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective.

Authors:  T G Mainprize; M D Taylor; J T Rutka; P B Dirks
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

Review 5.  Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas.

Authors:  A Besson; V W Yong
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

6.  Inducible expression of p57KIP2 inhibits glioma cell motility and invasion.

Authors:  K Sakai; A Peraud; T Mainprize; J Nakayama; A Tsugu; K Hongo; S Kobayashi; James T Rutka
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

7.  Effect of growth factors on the proliferation and gene expression of human meibomian gland epithelial cells.

Authors:  Shaohui Liu; Wendy R Kam; Juan Ding; Mark P Hatton; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-05       Impact factor: 4.799

8.  Boldine: a potential new antiproliferative drug against glioma cell lines.

Authors:  Daniéli Gerhardt; Ana Paula Horn; Mariana Maier Gaelzer; Rudimar Luiz Frozza; Andrés Delgado-Cañedo; Alessandra Luiza Pelegrini; Amélia T Henriques; Guido Lenz; Christianne Salbego
Journal:  Invest New Drugs       Date:  2008-12-03       Impact factor: 3.850

Review 9.  Aberrant cell cycle regulation in cervical carcinoma.

Authors:  Young Tae Kim; Min Zhao
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

Review 10.  Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases.

Authors:  Da-Zhi Liu; Bradley P Ander; Frank R Sharp
Journal:  Neurobiol Dis       Date:  2009-11-24       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.